It was heavily criticised from many quarters: the Healthy Heart Act.
The reallocation of funds away from the prevention of cardiovascular disease in favour of medication in particular has come under fire.
Changes are now planned that are intended to strengthen the use of disease management programmes (DMP). In essence, DMP would then already be opened up to people with statutory insurance who are at high risk of cardiovascular disease. Patients could therefore take part before the respective condition manifests itself.
For DiGA manufacturers this is relevant, because the DigiG provides for DiGA to be included in disease management programmes. This would recognise DiGA as a fixed component of standardised care for certain chronic conditions and integrate them into treatment plans. For diabetes mellitus, for example, this is already being planned concretely.
Fundamental criticisms of the act are not addressed by the planned changes, however.
Ärzteblatt summarises these in an article: Gesundes-Herz-Gesetz: Änderungen überzeugen Kritiker nicht